In the validation cohort, tumor number, size, age, differentiation, MVI, GGT, CD34, CD66b, Treg/CD8, CCR4-T, CCL17-T, CCL17-I, HHLA-2, CD73-T, and CCR4 + CD73 + cells have been proved to be prognostic variables for both OS and RFS in univariate analysis (all P < 0.050, Table 4). This evidence concerns the gene HHLA2 and neoplasm.